Citations (27)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (3)
Saverio Frosini, Fabrizio Franco, Giulio Vicini, Cristina Nicolosi, Gaia Varriale, Carlo Dani, Gianni Virgili & Fabrizio Giansanti. (2022) Efficacy and safety of intravitreal bevacizumab for the treatment of retinopathy of prematurity: a single-center retrospective review. The Journal of Maternal-Fetal & Neonatal Medicine 35:17, pages 3337-3342.
Read now
Read now
Qingyu Meng, Yong Cheng, Xi Wu, Dan Zhao, Mingwei Zhao & Jianhong Liang. (2020) Refractive error outcomes after intravitreal ranibizumab for retinopathy of prematurity. Clinical and Experimental Optometry 103:4, pages 495-500.
Read now
Read now
Samir N Patel & Michael A Klufas. (2019) Evidence to date: ranibizumab and its potential in the treatment of retinopathy of prematurity. Eye and Brain 11, pages 25-35.
Read now
Read now
Articles from other publishers (24)
Amparo Ortiz-Seller, Pablo Martorell, Honorio Barranco, Isabel Pascual-Camps, Esteban Morcillo & José L. Ortiz. (2024) Comparison of different agents and doses of anti-vascular endothelial growth factors (aflibercept, bevacizumab, conbercept, ranibizumab) versus laser for retinopathy of prematurity: A network meta-analysis. Survey of Ophthalmology.
Crossref
Crossref
Francesca Pascarella, Rosa Teresa Scaramuzzo, Alessandro Pini, Maurizio Cammalleri, Paola Bagnoli, Massimiliano Ciantelli & Luca Filippi. (2024) Propranolol: a new pharmacologic approach to counter retinopathy of prematurity progression. Frontiers in Pediatrics 12.
Crossref
Crossref
Jing Chen, Qingfei Hao, Jing Zhang, Yanna Du, Haoming Chen & Xiuyong Cheng. (2023) The efficacy and ocular safety following aflibercept, conbercept, ranibizumab, bevacizumab, and laser for retinopathy of prematurity: a systematic review and meta-analysis. Italian Journal of Pediatrics 49:1.
Crossref
Crossref
Niza Alva, Alex R. Martínez, Brando Ortiz-Saavedra, Elizbet S. Montes-Madariaga, Alonso Cotrina, José A. Caballero-Alvarado, Ranjit Sah & Joshuan J. Barboza. (2023) Ranibizumab for the treatment of retinopathy of prematurity: systematic review and meta-analysis. Frontiers in Pediatrics 11.
Crossref
Crossref
Neelam Pawar, D Somyashree, R Meenakshi, Devendra Maheshwari, Syed Mohideen & Mohammed Sithiq Uduman. (2023) Refractive profile of children treated with intravitreal bevacizumab for retinopathy of prematurity. Indian Journal of Ophthalmology 71:6, pages 2561-2568.
Crossref
Crossref
Jing-Ke Cao, Tao Han, Hong-Yi Tang, Sheng Zhang, Zong-Hua Wang, Zhi-Chun Feng & Qiu-Ping Li. (2023) Comparison of post-treatment recurrence between ranibizumab injection and laser photocoagulation for type 1 retinopathy of prematurity. BMC Ophthalmology 23:1.
Crossref
Crossref
Eşay Kıran Yenice, İkbal Seza Petriçli & Caner Kara. (2022) One-year refractive outcomes after intravitreal bevacizumab versus laser photocoagulation for retinopathy of prematurity. International Ophthalmology 43:7, pages 2197-2202.
Crossref
Crossref
Ghada Mahmoud Tawfik, Ezzat A Shahein, Sherif A Dabour, Dina Hassanein & Ahmed Mohamed Elshewy. (2022) Comparison of intravitreal injection of ranibizumab versus bevacizumab for treatment of type 1 and aggressive retinopathy of prematurity in rural Egypt. A randomized clinical trial. BMJ Open Ophthalmology 7:1, pages e001173.
Crossref
Crossref
Emer Chang, Amandeep S. Josan, Ravi Purohit, Chetan K. Patel & Kanmin Xue. (2022) A Network Meta-Analysis of Retreatment Rates following Bevacizumab, Ranibizumab, Aflibercept, and Laser for Retinopathy of Prematurity. Ophthalmology 129:12, pages 1389-1401.
Crossref
Crossref
Georgios N. Tsiropoulos, Aikaterini K. Seliniotaki, Anna-Bettina Haidich, Nikolaos Ziakas & Asimina Mataftsi. (2022) Comparison of adverse events between intravitreal anti-VEGF and laser photocoagulation for treatment-requiring retinopathy of prematurity: a systematic review. International Ophthalmology 43:3, pages 1027-1062.
Crossref
Crossref
Sadik Etka Bayramoglu, Nihat Sayin & Dilbade Yildiz Ekinci. (2022) Refractive outcomes following unilateral laser treatment for type 1 retinopathy of prematurity. Journal of American Association for Pediatric Ophthalmology and Strabismus 26:5, pages 245.e1-245.e6.
Crossref
Crossref
Nada O. Taher, Abdullah A. Ghaddaf, Sarah A. Al-Ghamdi, Jumanah J. Homsi, Bandar J. Al-Harbi, Lugean K. Alomari & Hashem S. Almarzouki. (2022) Intravitreal Anti-vascular Endothelial Growth Factor Injection for Retinopathy of Prematurity: A Systematic Review and Meta-Analysis. Frontiers in Medicine 9.
Crossref
Crossref
Aldo Bancalari & Ricardo Schade. (2020) Update in the Treatment of Retinopathy of Prematurity. American Journal of Perinatology 39:01, pages 022-030.
Crossref
Crossref
Jianbing Ren, Jingbo Jiang, Weiming Ou, Xianqiong Luo, Jianwen Xiang, Guosheng Liu, Shuiqing Huang, Longkai He, Jiamin Gan, Hongping Li & Chuan Nie. (2021) The Effect of STAT3 Signal Pathway Activation on Retinopathy of Prematurity. Frontiers in Pediatrics 9.
Crossref
Crossref
Joshua M. Barnett & G. Baker Hubbard. (2021) Complications of retinopathy of prematurity treatment. Current Opinion in Ophthalmology 32:5, pages 475-481.
Crossref
Crossref
Marko M. Popovic, Prem Nichani, Rajeev H. Muni, Kamiar Mireskandari, Nasrin N. Tehrani & Peter J. Kertes. (2021) Intravitreal antivascular endothelial growth factor injection versus laser photocoagulation for retinopathy of prematurity: A meta-analysis of 3,701 eyes. Survey of Ophthalmology 66:4, pages 572-584.
Crossref
Crossref
Qihang Kong, Wai-kit Ming & Xue-Song Mi. (2021) Refractive outcomes after intravitreal injection of antivascular endothelial growth factor versus laser photocoagulation for retinopathy of prematurity: a meta-analysis. BMJ Open 11:2, pages e042384.
Crossref
Crossref
Qing-Qing Tan, Stephen P. Christiansen & Jingyun Wang. (2019) Development of refractive error in children treated for retinopathy of prematurity with anti-vascular endothelial growth factor (anti-VEGF) agents: A meta-analysis and systematic review. PLOS ONE 14:12, pages e0225643.
Crossref
Crossref
Ramak Roohipoor, Hamidreza Torabi, Reza Karkhaneh & Mohammad Riazi-Eafahani. (2019) Comparison of intravitreal bevacizumab injection and laser photocoagulation for type 1 zone II retinopathy of prematurity. Journal of Current Ophthalmology 31:1, pages 61-65.
Crossref
Crossref
Yunxia Leng, Wenzhi Huang, Guoliang Ren, Cheng Cai, Qingbiao Tan, Yuqin Liang, Weizhong Yang & Zongyin Gao. (2018) The treatment and risk factors of retinopathy of prematurity in neonatal intensive care units. BMC Ophthalmology 18:1.
Crossref
Crossref
Gillian GW Adams, Catey Bunce, Wen Xing, Lucilla Butler, Vernon Long, Aravind Reddy & Annegret H. Dahlmann-Noor. (2018) Retinopathy of prematurity in the United Kingdom: retreatment rates, visual and structural 1-year outcomes. Eye 32:11, pages 1752-1759.
Crossref
Crossref
Gökhan Pekel & Evre Pekel. (2018) Re: Vogel et al.: Foveal development in infants treated with bevacizumab or laser photocoagulation for retinopathy of prematurity (Ophthalmology. 2018;125:444-452). Ophthalmology 125:8, pages e56-e57.
Crossref
Crossref
Yung-Sung Lee, Lai-Chu See, Shu-Hao Chang, Nan-Kai Wang, Yih-Shiou Hwang, Chi-Chun Lai, Kuan-Jen Chen & Wei-Chi Wu. (2018) Macular Structures, Optical Components, and Visual Acuity in Preschool Children after Intravitreal Bevacizumab or Laser Treatment. American Journal of Ophthalmology 192, pages 20-30.
Crossref
Crossref
Mari Jeeva Sankar, Jhuma Sankar & Parijat Chandra. (2018) Anti-vascular endothelial growth factor (VEGF) drugs for treatment of retinopathy of prematurity. Cochrane Database of Systematic Reviews 2018:1.
Crossref
Crossref